Target Name: MVB12A
NCBI ID: G93343
Other Name(s): CIN85/CD2AP family-binding protein | ESCRT-I complex subunit MVB12A | MVB12A variant 2 | MB12A_HUMAN | Multivesicular body subunit 12A isoform 1 | Multivesicular body subunit 12A, transcript variant 1 | Multivesicular body subunit 12A (isoform 1) | Multivesicular body subunit 12A | CFBP | Multivesicular body subunit 12A, transcript variant 2 | family with sequence similarity 125, member A | Family with sequence similarity 125, member A | MVB12A variant 1 | Multivesicular body subunit 12A isoform 2 | FAM125A | Protein FAM125A | multivesicular body subunit 12A | CIN85/CD2AP family binding protein

MVB12A: A Promising Drug Target and Biomarker for Chronic Inflammatory Diseases

Introduction

Chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and chronic obstructive pulmonary disease (COPD), affect millions of people worldwide and cause significant morbidity and mortality. The immune system's persistent response to environmental triggers can lead to chronic inflammation, resulting in ongoing tissue damage and impaired function. MVB12A, a protein that belongs to the CIN85/CD2AP family, has been identified as a potential drug target and biomarker for these chronic inflammatory diseases.

MVB12A: Structure and Function

MVB12A is a 12-kDa protein that is expressed in various tissues, including the brain, spleen, and Peyer's patches of the intestine. It is characterized by a N-terminal extracellular domain (ECD), a transmembrane region (TMD), and a C-terminal TIR domain. The TIR domain is responsible for MVB12A's unique structural features, including a conserved helix-loop structure and a N-terminal hypervariable region (NHR).

MVB12A functions as a cell adhesion molecule, participating in the development and maintenance of tight junctions, which are specialized barrier systems that regulate the movement of ions and solutes into and out of cells. tight junctions are critical for maintaining tissue homeostasis and for Preventing excessive water and ion transport, which are major factors in the development of chronic inflammatory diseases.

MVB12A has been shown to play a crucial role in the regulation of inflammation and autoimmunity. It has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-伪, IL-1尾, and IL-6, by suppressing the activity of nuclear factor kappa B (NF-kappa-B). Additionally, MVB12A has been shown to modulate the activity of T cells, playing a key role in the regulation of CD4+ and CD8+ T cell responses.

MVB12A has also been shown to be involved in the regulation of inflammation-associated pain. It has been shown to contribute to the development of pain in inflammatory diseases, and to have a negative effect on pain perception.

Drug Targeting and Biomarker Potential

The persistent inflammation caused by chronic inflammatory diseases can be a difficult-to-treat problem. The MVB12A protein, with its unique structure and function, makes it an attractive drug target. MVB12A has been shown to be a potential therapeutic target in various models of chronic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and COPD.

In rheumatoid arthritis, MVB12A has been shown to regulate the production of pro-inflammatory cytokines and to contribute to the development of joint damage. Similarly, in inflammatory bowel disease, MVB12A has been shown to promote the recruitment of immune cells to the mucosal surface, contributing to the development of inflammatory changes.

In addition to its potential therapeutic impact, MVB12A may also be used as a biomarker for monitoring the progression of chronic inflammatory diseases. The levels of MVB12A have been shown to be elevated in individuals with rheumatoid arthritis, and to be associated with the severity of disease. Similarly, MVB12A has been shown to be elevated in individuals with inflammatory bowel disease, and to be associated with the severity of disease.

Conclusion

MVB12A is a protein that has the potential to be a drug target for chronic inflammatory diseases. Its unique structure and function, as well as its involvement in the regulation of inflammation and autoimmunity, make it an attractive target for further study. Further research is needed to fully understand the role of MVB12A in the development and progression of chronic inflammatory diseases.

1.

Protein Name: Multivesicular Body Subunit 12A

Functions: Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies. May be involved in the ligand-mediated internalization and down-regulation of EGF receptor

More Common Targets

MVB12B | MVD | MVK | MVP | MX1 | MX2 | MXD1 | MXD3 | MXD4 | MXI1 | MXRA5 | MXRA5Y | MXRA7 | MXRA8 | MYADM | MYADML | MYADML2 | MYB | MYBBP1A | MYBL1 | MYBL2 | MYBPC1 | MYBPC2 | MYBPC3 | MYBPH | MYBPHL | MYC | MYCBP | MYCBP2 | MYCBP2-AS1 | MYCBPAP | MYCL | MYCL-AS1 | MYCLP1 | MYCN | MYCNOS | MYCNUT | MYCT1 | MYD88 | MYDGF | MYEF2 | Myelin Protein | MYEOV | MYF5 | MYF6 | MYG1 | MYH1 | MYH10 | MYH11 | MYH13 | MYH14 | MYH15 | MYH16 | MYH2 | MYH3 | MYH4 | MYH6 | MYH7 | MYH7B | MYH8 | MYH9 | MYHAS | MYL1 | MYL10 | MYL11 | MYL12A | MYL12B | MYL12BP3 | MYL2 | MYL3 | MYL4 | MYL5 | MYL6 | MYL6B | MYL7 | MYL9 | MYLIP | MYLK | MYLK-AS1 | MYLK-AS2 | MYLK2 | MYLK3 | MYLK4 | MYLKP1 | MYMK | MYMX | MYNN | MYO10 | MYO15A | MYO15B | MYO16 | MYO16-AS1 | MYO16-AS2 | MYO18A | MYO18B | MYO19 | MYO1A | MYO1B | MYO1C | MYO1D